Genomic signature of trastuzumab neoadjuvant therapy predictive of patient survival in HER2-positive breast cancer

被引：0
|
作者：
Briones, Natalia [1 ]
Facista, Salvatore [1 ]
Halperin, Rebecca [1 ]
Heaton, Paul [2 ]
Mahadevan, Daruka [3 ]
Hendricks, Wiiliam [1 ]
Kim, Suwon [2 ]
机构：
[1] Translat Genom Res Inst, Phoenix, AZ USA
[2] Univ Arizona, Coll Med Phoenix, Phoenix, AZ USA
[3] Univ Arizona, Ctr Canc, Tucson, AZ USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-3412
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3412
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [41] Neoadjuvant treatment for HER2-positive breast cancer
    Takada, Masahiro
    Toi, Masakazu
    [J]. CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [42] Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
    Untch, Michael
    Rezai, Mahdi
    Loibl, Sibylle
    Fasching, Peter A.
    Huober, Jens
    Tesch, Hans
    Bauerfeind, Ingo
    Hilfrich, Joern
    Eidtmann, Holger
    Gerber, Bernd
    Hanusch, Claus
    Kuehn, Thorsten
    du Bois, Andreas
    Blohmer, Jens-Uwe
    Thomssen, Christoph
    Costa, Serban Dan
    Jackisch, Christian
    Kaufmann, Manfred
    Mehta, Keyur
    von Minckwitz, Gunter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2024 - 2031
  • [43] Pertuzumab plus trastuzumab increases survival in patients with HER2-positive breast cancer
    Mayor, Susan
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (11) : 611 - 611
  • [44] Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Nakatsukasa, Katsuhiko
    Taguchi, Tetsuya
    Sugimoto, Riho
    Sakaguchi, Kouichi
    Kotani, Tatsuya
    Hukuda, Kenichirou
    Kawakami, Sadao
    Hujiwara, Ikuya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Trastuzumab after adjuvant chemotherapy: survival benefit in HER2-positive breast cancer
    [J]. Nature Clinical Practice Oncology, 2007, 4 (4): : 208 - 209
  • [46] Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
    Hall, Benjamin James
    Bhojwani, Ajay Ashok
    Wong, Helen
    Law, Andrea
    Flint, Helen
    Ahmed, Eliyaz
    Innes, Helen
    Cliff, Joanne
    Malik, Zaf
    O'Hagan, Julie Elizabeth
    Hall, Allison
    Sripadam, Rajaram
    Tolan, Shaun
    Ali, Zulfiqar
    Hart, Clare
    Errington, Douglas
    Alam, Farida
    Giuliani, Rosa
    Mehta, Shaveta
    Khanduri, Sheena
    Thorp, Nicky
    Jackson, Richard
    Cicconi, Silvia
    Palmieri, Carlo
    [J]. BREAST JOURNAL, 2022, 2022
  • [47] Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer.
    Kulkarni, S.
    Redd, K. B.
    Esteva, F. J.
    Budd, G. T.
    Moore, H. C. F.
    Tubbs, R. R.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 161S - 161S
  • [48] Pathological complete response and survival of HER2-positive invasive breast cancer following docetaxel, carboplatin, and trastuzumab neoadjuvant therapy: a Vietnamese experience
    Le, Duc Thanh
    Do, Tu Anh
    Bui, Lap Thanh
    Do, Kien Hung
    Nguyen, Chu Van
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (04): : 235 - 243
  • [49] Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer - an Analysis of a Large University Breast Cancer Centre
    Matovina, Sabine
    Engler, Tobias
    Volmer, Lea-Louise
    Mueller, Heike
    Grischke, Eva-Maria
    Staebler, Annette
    Hahn, Markus
    Brucker, Sara Yvonne
    Hartkopf, Andreas Daniel
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (06) : 694 - 701
  • [50] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    [J]. LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
12345